Business Wire

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and ...
Business Wire

Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and ...

CD73 Inhibitors Pipeline Report 2025: an Up-to-date Competitor Evaluation in the Field of Antibodies, RNA and Small Molecules in Research and Development Inhibiting CD73

CD73 inhibitors offer significant market opportunities in cancer treatment through novel immunotherapies. Promising developments include monoclonal antibodies, nucleotides, and non-nucleotides, with ...
EurekAlert!

Oncotarget: Targeting breast cancer metabolism with a novel inhibitor

Oncotarget recently published "Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis" by Kim, et al. which reported that the authors show that CADD522 inhibits ...
ascopubs.org

Results of a phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies

A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid ...